In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to ...

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences ...

Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to their trading decisions The top 15 shareholders own 50% of the company Ownership research ...

Two years after the St George’s High School was destroyed by a fire, the school was rebuilt and renamed the St George’s School of Sciences. Minister of Education Priya Manickchand on Monday visited ...

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...

Gilead Sciences, Virtus Investment Partners and Hess Midstream have rewarded their shareholders for more than a decade and recently announced dividend hikes. These companies offer high dividend ...

GS-9716 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR ...

Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 10 unusual trades. Delving into the details, we found 20 ...